Dr Gershenson was the only gynaecological cancer specialist acknowledged in this year’s award which highlights his expertise and contribution to the field. He has dedicated the award to all of his low-grade serous cancer patients and families. His research has influenced the treatments of low-grade serous cancer patients around the world.
Unprecedented response rate in neoadjuvent trial for low-grade serous cancer
A Phase 2 study of 15 women with low-grade serous ovarian cancer reported by investigators from the University of Texas MD Anderson Cancer Center found an “unprecedented response rate” with … Read More
Latest updates in low grade serous ovarian cancer treatment and research
“I’m pleased that we are living in times where progress is being made, and trials are being done because previously there weren’t trials specifically for low-grade serous cancer.” – Dr … Read More
Dr Banerjee gives update on Phase 1/2 Frame trial for RAF/MEK/FAK inhibitor
Dr Susana Banerjee recently presented the updated results of the Verastem Phase 1/2 clinical trial (Frame study) at this years’s ESMO (the European Society for Medical Oncology) Congress. The results … Read More
Is chemotherapy necessary in newly diagnosed low-grade serous cancer?
One of the difficulties with low-grade serous ovarian cancer is that a lack of data and research can make it difficult for doctors to know what is the most appropriate … Read More
